m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00716)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
EphA2
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
| Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
| Cell Line | Caco-2 cell line | Homo sapiens |
|
Treatment: shMETTL3 Caco-2 cells
Control: shNTC Caco-2 cells
|
GSE167075 | |
| Regulation |
![]() ![]() |
logFC: 6.09E-01 p-value: 1.09E-18 |
| More Results | Click to View More RNA-seq Results | |
| Representative RIP-seq result supporting the interaction between EphA2 and the regulator | ||
| Cell Line | MDA-MB-231 | Homo sapiens |
| Regulation | logFC: 1.66E+00 | GSE60213 |
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) [READER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP2-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Target Regulation | Up regulation | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP3-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Target Regulation | Up regulation | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Colorectal cancer [ICD-11: 2B91]
| In total 3 item(s) under this disease | ||||
| Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP2-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
| Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
| Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP3-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
| Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | READER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
| Experiment 3 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | Ephrin type-A receptor 2 (EphA2) and VEGFA targeted by METTL3 via different IGF2BP-dependent mechanisms were found to promote vasculogenic mimicry (VM) formation via PI3K/AKT/mTOR and ERK1/2 signaling in CRC. | |||
| Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
| In-vitro Model | SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| NCM460 | Normal | Homo sapiens | CVCL_0460 | |
| LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
| HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
| HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | |
| In-vivo Model | A total of 8 × 106 wild-type (WT) or METTL3-knockdown cells were injected into the dorsal flanks of 6-week-old nude mice. Seven mice were randomly selected to calculate the volume according to the following formula: V = (width2 × length)/2. Mice were euthanized three weeks after injection and tumors removed, weighed, fixed, and embedded for immunohistochemical analysis. | |||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Regulator
Histone modification
m6A Regulator: Methyltransferase-like 3 (METTL3)
| In total 2 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT03578 | ||
| Epigenetic Regulator | Histone acetyltransferase p300 (P300) | |
| Regulated Target | Histone H3 lysine 27 acetylation (H3K27ac) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |
| Crosstalk ID: M6ACROT03623 | ||
| Epigenetic Regulator | N-lysine methyltransferase SMYD2 (SMYD2) | |
| Regulated Target | Histone H3 lysine 4 trimethylation (H3K4me3) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |

